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Genetic studies have identiﬁed thousands of variants associated with complex traits. However, most association
studies are limited to populations of European descent and a single phenotype. The Population Architecture using
Genomics and Epidemiology (PAGE) Study was initiated in 2008 by the National Human Genome Research
Institute to investigate the epidemiologic architecture of well-replicated genetic variants associated with complex
diseases in several large, ethnically diverse population-based studies. Combining DNA samples and hundreds of
phenotypes from multiple cohorts, PAGE is well-suited to address generalization of associations and variability of
effects in diverse populations; identify genetic and environmental modiﬁers; evaluate disease subtypes, interme-
diate phenotypes, and biomarkers; and investigate associations with novel phenotypes. PAGE investigators
harmonize phenotypes across studies where possible and perform coordinated cohort-speciﬁc analyses and
meta-analyses. PAGE researchers are genotyping thousands of genetic variants in up to 121,000 DNA samples
from African-American, white, Hispanic/Latino, Asian/Paciﬁc Islander, and American Indian participants. Initial anal-
yses will focus on single nucleotide polymorphisms (SNPs) associated with obesity, lipids, cardiovascular disease,
type2diabetes,inﬂammation,variouscancers,andrelatedbiomarkers.PAGESNPsare also assessed for pleiotropy
using the ‘‘phenome-wide association study’’ approach, testing each SNP for associations with hundreds of
phenotypes. PAGE data will be deposited into the National Center for Biotechnology Information’s Database of
Genotypes and Phenotypes and made available via a custom browser.
cardiovascular diseases; cohort studies; genome-wide association study; multifactorial inheritance; neoplasms;
obesity; population characteristics; reproducibility of results
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CALiCo, Causal Variants Across the Life Course; CARDIA, Coronary
Artery Risk Development in Young Adults; dbGaP, Database of Genotypes and Phenotypes; EAGLE, Epidemiologic Architecture
for Genes Linked to Environment; GWAS, genome-wide association study(ies); NHANES, National Health and Nutrition Exam-
ination Surveys; NHGRI, National Human Genome Research Institute; NIH, National Institutes of Health; PAGE, Population
Architecture using Genetics and Epidemiology; SNP, single nucleotide polymorphism.
Genome-wide association studies (GWAS) have been suc-
cessful in conﬁrming and identifying numerous loci related to
complex human traits, resulting in the compilation of hundreds
of unique single nucleotide polymorphism (SNP)-trait associ-
ationsatthelevelofgenome-widesigniﬁcance(P  53 10
 8)
(1). Though these GWAS successes are considerable, most
originate from populations of European descent (2, 3), and
it is not yet clear to what extent associations conﬁrmed in
one population are generalizable to other populations such
as African Americans and Hispanics. Differences in genetic
background and environment may alter the effect of causal
variants. Further, differences in linkage disequilibrium patterns
849 Am J Epidemiol. 2011;174(7):849–859may modify observed associations of nonfunctional SNPs
(i.e., index signals). Given these factors, the determination
of causal variants, their roles in gene function, their connec-
tions to complex traits, their interaction with known risk
factors, and their potential for clinical translation requires
making substantial progress beyond GWAS (4–6). Laying
theinitialgroundworkincludesevaluation ofthefullbreadth
of phenotypic associations of highly replicated GWAS-
deﬁned variants and their allele frequencies on a population
basis, particularly in populations of non-European ancestry.
ThePopulation Architecture using Genomics and Epidemi-
ology (PAGE) Study (http://www.pagestudy.org) is a National
Human Genome Research Institute (NHGRI)-created consor-
tium of large, well-characterized population-based studies
that provides an unprecedented opportunity to investigate the
epidemiologicarchitectureof well-replicated genetic variants
associated with complex diseases. Just as genetic architecture
describes the genomic inﬂuences underlying a phenotypic
trait, epidemiologic architecture describes population-level
phenotypes, exposures, and ancestry that modify a speciﬁc
genetic effect and inﬂuence its population impact.
PAGE investigators have expertise in epidemiology, genet-
ics, biostatistics, bioinformatics, and various common complex
diseases. The PAGE consortium consists of 4 large, ongoing
population-based studies or consortia: Epidemiologic Archi-
tecture for Genes Linked to Environment (EAGLE), which
is based on data from 3 National Health and Nutrition Ex-
amination Surveys (NHANES;https://chgr.mc.vanderbilt.edu/
eagle) (7); the Multiethnic Cohort Study (http://www.crch.
org/multiethniccohort/) (8); the Women’s Health Initiative
(http://www.whi.org)(9);andCausalVariantsAcrosstheLife
Course(CALiCo), a consortiumof5 cohortstudies—Athero-
sclerosis Risk in Communities (ARIC; http://www.cscc.unc.
edu/aric/) (10), Coronary Artery Risk Development in Young
Adults (CARDIA; http://www.cardia.dopm.uab.edu/) (11),
the Cardiovascular Health Study (http://www.chs-nhlbi.
org/) (12), the Hispanic Community Health Study/Study of
Latinos (http://www.cscc.unc.edu/hchs/) (13), and the Strong
Heart Study (http://strongheart.ouhsc.edu/) (14, 15). A coor-
dinating center provides operational and scientiﬁc support,
while the NHGRI Ofﬁce of Population Genomics partici-
pates in study design, scientiﬁc support, and assessment
of progress. With over 121,200 African-American, white,
Hispanic/Latino, Asian/Paciﬁc Islander, and American Indian
participants available for study across the cohorts, PAGE
investigators are well poised to address the critical research
questions that follow the establishment of GWAS associa-
tions through large-scale replication and generalization.
In this paper, we describe the PAGE consortium, including
its goals, organization, data sets, methods, and study design,
and highlight how PAGE can contribute to understanding
the genetic and epidemiologic architecture of conﬁrmed,
associated genetic variants.
MATERIALS AND METHODS
PAGE Study goals
The PAGE Study is designed to reﬁne knowledge on the
epidemiologic architecture of common genetic variants asso-
ciated with human diseases and traits. To address this need,
PAGE investigators will evaluate the index signals from
GWAS or biologically relevant alleles (i.e. ‘‘causal’’ alleles)
according to these objectives:
1. Assessing the generalizability of the phenotype-variant
association to other populations.
2. Comparing the strength of the effects in various subgroups.
These subgroups are deﬁned by race/ethnicity and other
demographic characteristics; exposures, risk proﬁles, and
disease characteristics; and social contexts.
3. Estimating the burden of disease, including relative risks
of incident disease, associated with genetic variants in
population-based settings.
4. Characterizingeffectmodiﬁcationbygeneticandenviron-
mental factors, including lifestyle, comorbidity, and med-
ication use.
5. Extending results to disease subtypes, related biomarkers,
intermediate phenotypes, and precursors.
6. Assessing pleiotropic effectsbyinvestigating associations
withphenotypesunrelatedtothose reportedinthe original
studies.
Addressing these objectives will help PAGE researchers de-
termine whether a variant is causal and select candidate
variants for in-depth functional studies. PAGE may also iden-
tify phenotypic characteristics that provide clues to the un-
derlying biologic effects of the variants under study.
To accomplish these goals, the PAGE investigators have
developed approaches to streamline prioritization of partic-
ipants and SNPs to be genotyped, harmonize phenotypes
across studies, assess quality control for genotype and pheno-
type data, and explore new analytic methods. Because these
considerations are relevant to ongoing and future studies of
population genomics, particularly in the context of multisite
meta-analyses, an additional goal of PAGE researchers is
to describe PAGE approaches so they may aid the scientiﬁc
community.
The breadth of phenotype data available in each PAGE
data set permits hundreds of phenotypes to be tested against
each genotyped SNP in a ‘‘phenome-wide association study.’’
In contrast to a GWAS, which tests many SNPS for associa-
tion with 1 phenotype or a few phenotypes, a phenome-wide
association study explores the relations of many phenotypes
with 1 SNP or a few SNPs (16). This type of study has the
potential to identify pleiotropic associations that can provide
clues to functional implications of GWAS-deﬁned SNPs
and may provide other insights into pathobiology. Finally, to
help synthesize results across studies and present these data
in a visually intuitive manner, PAGE investigators are devel-
oping customized graphical browser software for exploring
these results.
PAGE Study organization
The PAGE Study is a collaborative effort between 4 pro-
jects representing 8 large population-based studies, a co-
ordinating center, and the NHGRI Ofﬁce of Population
Genomics. PAGE began in 2008 in response to NHGRI so-
licitations for applications for study sites and a coordinating
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ducted in approximately annual cycles.
Figure 1 shows the overall organizationofthe PAGE Study.
The Steering Committee meets often (by teleconference or
in person) to review priorities and progress, discuss the study
design and analyses, and resolve problems. The NHGRI
Ofﬁce of Population Genomics participates in working groups
and subcommittees and helps set research priorities, develop
program policies, and coordinate activities among PAGE in-
vestigators. The Coordinating Center assists with integration,
synthesis, quality control, and dissemination of study results
and data via the National Center for Biotechnology Informa-
tion’s Database of Genotypes and Phenotypes (dbGaP) (19).
The Coordinating Center also develops novel data display
Figure 1. Organizational structure of the Population Architecture Using Genomics and Epidemiology (PAGE) Study, 2008–present. The PAGE
Steering Committee (purple box, center) comprises principal investigators from the individual studies and the Coordinating Center and the National
Human Genome Research Institute project scientist. Multiple investigators from each of these groups participate in working groups (WGs) and
committees (brown boxes) which are tasked with speciﬁc responsibilities (light blue boxes) to facilitate analysis, publication, and disseminationo f
PAGE results. Genotyping, quality control (QC), and statistical analysis are performed by researchers in the individual studies with guidance from
the Steering Committee and assistance from the Coordinating Center. Project and writing groups are organized to produce topic-speciﬁc manu-
scripts for the purpose of publication in peer-reviewed journals; the minor distinction between the 2 groups deals with the scope of the analysis
(project groups tend to include more studies and produce multiple manuscripts). In parallel, the Coordinating Center performs an additional level
of QC on the association-level data from each study, preparing these aggregate data for dissemination via the PAGE data browser, a user-friendly
resource for viewing PAGE results. PAGE data will also be available in the National Center for Biotechnology Information’s (NCBI) Database
of Genotypes and Phenotypes (dbGaP). NIH, National Institutes of Health; SNP, single nucleotide polymorphism.
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tics.Workinggroupsandcommitteesare organizedasneeded
to make optimal use of expertise among all PAGE partici-
pants. All working groups and committees comprise repre-
sentativesfrom all participating studies, with focused efforts
to include postdoctoral fellows and new investigators.
Study populations
The PAGE network includes 4 population-based projects.
Each study includes 15,000–160,000 participants, for whom
extensive phenotype, covariate, and exposure data, as well as
high-quality DNA, are available for analysis (Table 1). The
PAGE studies include participants from a variety of ethnic
populations (Table 2). The researchers in all PAGE studies
obtained institutional review board approval, and all subjects
provided written informed consent. These studies have evalu-
ated thousands of phenotypes, with substantial overlap across
the PAGE studies (Table 3) and ancestry groups (Table 4).
The individual study Web sites provide additional descriptive
details.
The large sample sizes allow for a variety of powerful
analyses that include both replication and discovery oppor-
tunities. For example, a PAGE-wide analysis of low density
lipoprotein cholesterol levels (measured in mg/dL) exclud-
ing nonfasting participants under 18 years of age includes
21,986 European Americans, 9,328 African Americans, 6,144
American Indians, and 2,532 Mexican Americans/Hispanics.
Using Quanto (20) and assuming an additive genetic model
with a ¼ 0.005, we have at least 80% power to replicate
associations with effect sizes (b) as low as 1.26 (European
Americans), 2.08 (African Americans), 2.07 (American In-
dians), and 3.46 (Mexican Americans/Hispanics), depending
on allele frequency. These genetic effect sizes are similar to
the effect estimates reported in most GWAS for low density
lipoprotein cholesterol (see Web Table 1, available on the
Journal’s Web site (http://aje.oxfordjournals.org/)). Power will
vary from analysis to analysis given the range of phenotypes,
the list of exclusions, the number of strata, the minor allele
frequency of the SNP(s), the number of PAGE sites that
genotype each SNP, and the effect sizes expected for each
association.
Phenotype harmonization and subject selection
Collectively, PAGE investigators identify the phenotypes to
focus on for each genotyping and analysis cycle. The focus
phenotypes are selected to strike a balance between those
that are common to multiple studies and those that are spe-
ciﬁc to individual studies. Higher priority is considered for
Table 1. Characteristics of Cohorts Included in the Population Architecture Using Genomics and Epidemiology (PAGE) Study, 2008–present
Study Study Type Focus of
Study
Years of Data
Collection
Length of
Follow-up,
years
b
Mean
Age,
years
Age
Range,
years
% Women Genotyping Platform(s)
Used
EAGLE Study Cross-sectional
a American
health
1991–1994,
1999–2002
N/A 35 12–95 54 Applied Biosystems TaqMan
(Applied Biosystems, Foster
City, California), TaqMan
OpenArray (Applied
Biosystems), Sequenom
iPlex (Sequenom, San Diego,
California), Illumina
BeadXpress (Illumina, Inc.,
San Diego, California)
Multiethnic Cohort
Study
Nested case-
control
Cancer 1993–1996 17 60 45–78 55 Applied Biosystems TaqMan,
TaqMan OpenArray
Women’s Health
Initiative
Cohort and
clinical trials
Women’s
health
1993–1998 17 63 50–79 100 Illumina BeadXpress
CALiCo
Consortium
ARIC Study Longitudinal Cardiovascular
disease
1987–present 24 54 45–64 55.1 Applied Biosystems TaqMan,
Sequenom iPlex
CARDIA Study Longitudinal Cardiovascular
disease
1986–present 25 25 18–30 54.4 Applied Biosystems TaqMan,
Sequenom iPlex
Cardiovascular
Health Study
Longitudinal Cardiovascular
disease
1988–1999 18 73 65–100 57.6 Applied Biosystems TaqMan,
Sequenom iPlex
Strong Heart
Study
Longitudinal Cardiovascular
disease
1988–present 23 40 14–91 59.3 Applied Biosystems TaqMan,
Sequenom iPlex
Hispanic
Community
Health Study/
Study of
Latinos
Longitudinal Cardiovascular
disease
2008–present 3 55 18–72 65 Applied Biosystems TaqMan,
Sequenom iPlex
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CALiCo, Causal Variants Across the Life Course; CARDIA, Coronary Artery Risk
Development in Young Adults; EAGLE, Epidemiologic Architecture for Genes Linked to Environment; N/A, not applicable; NHANES, National
Health and Nutrition Examination Survey.
a The EAGLE study analyzes data from phase 2 of the Third National Health and Nutrition Examination Survey (NHANES III) and NHANES
1999–2002.
b Participant follow-up is ongoing; years shown are the maximum number of follow-up years as of the date of publication.
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differing prevalences across ethnic groups, and phenotypes
with robustly replicated SNP associations. Studywide, in the
ﬁrst 2 years, PAGE investigators are analyzing phenotypes
associated with cardiovascular disease, lipids, stroke, type 2
diabetes, a variety of cancers, and smoking; anthropometric
and electrocardiographic traits; ages at menopause and men-
arche; and a variety of biomarkers.
Prior to analyses, phenotype harmonization must occur,
whereby phenotypic variables are identiﬁed that have had
data collected using similar methods across all or most par-
ticipating studies. For covariate and exposure phenotypes
(such as smoking, alcohol consumption, diet, medical his-
tory, family history, medication use, and socioeconomic sta-
tus), an investigator from each study creates an inventory of
variables related to that phenotype, including assay param-
eters and/or speciﬁc questionnaires. Each study investigator
also participates in a working group to identify commonly
ascertained variables and to recommend speciﬁc variables
for use in analyses. Trait distributions are compared across
studies to deﬁne new harmonized variables as appropriate.
Subject selection varies by site, since each study must
balance the number of variants and participants genotyped
within available budgets. EAGLE and CALiCo are genotyping
all participants in the data set who have information on the
studied phenotype and DNA available. In the larger cohorts,
such as the Women’s Health Initiative and the Multiethnic
Cohort Study, the investigators select subsets of participants
and maximize sample sizes for available phenotypes and eth-
nicgroups.Subsetsareidentiﬁedthatwillprovideasubstantial
sample size (cases and controls) for each of the PAGE focus
phenotypes while preferentially including participants who
also have relevant biomarker measurements.
SNP selection and genotyping methods
Once focus phenotypes are determined for a genotyping
and analysis cycle, the published literature is searched to
identify associated SNPs to use for PAGE analysis. The
NHGRI GWAS catalog (1) is especially useful for these
searches. Sincethestudiesvaryingenotypingcapacityandin
available phenotypes, researchers in each study then choose
a custom SNP set from the jointly determined SNPs of
interest.
Genotyping in PAGE is performed separately by the in-
vestigators in each study, which requires detailed guidelines
for consistent quality control. Theseguidelines includethresh-
olds for SNP and sample call rates (>90%), concordance of
blinded replicates (>98%), and no clear evidence of Hardy-
Weinberg disequilibrium (P > 0.001), which is evaluated
within and across studies and in each racial/ethnic popula-
tion. For each cycle, each laboratory genotypes 360 HapMap
samples (from populations most relevant to PAGE) to serve
as cross-laboratory andcross-platform quality control samples
(http://hapmap.ncbi.nlm.nih.gov/). The Coordinating Center
performs quality control analyses on the HapMap genotypes,
including concordancy with p u b l i s h e dH a p M a pd a t aa n d
across PAGE studies, detection of Mendelian errors in trios,
and evaluation of Hardy-Weinberg equilibrium. Quality con-
trol results are shared across studies and are discussed within
Table 2. Number of Participants in Each Study Included in the Population Architecture Using Genomics and Epidemiology (PAGE) Study, by
Race/Ethnicity, 2008–present
Ethnic/Racial
Group
CALiCo Consortium
a EAGLE Study Women’s Health
Initiative Multiethnic Cohort Study Total
Total No.
With DNA
b
No. of
Persons
Analyzed
c
Total No.
With DNA
No. of
Persons
Analyzed
Total No.
With DNA
No. of
Persons
Analyzed
Total No.
With DNA
No. of
Persons
Analyzed
Total No.
With DNA
No. of
Persons
Analyzed
White 18,093 18,093 6,634 6,634 118,347 26,246 14,699 6,441 157,773 57,414
Hispanic/Latino
d 6,500
e 0
e 3,950 3,950 5,367 2,430 18,086 8,909 33,903 15,289
African-American 7,203 7,203 3,458 3,458 11,924 5,218 11,279 8,030 33,864 23,909
Asian/Paciﬁc
Islander
f 47 47 3,474 1,954 Japanese:
24,676 11,774
33,760 16,975
Native
Hawaiian:
5,563 3,200
American Indian 7,283 7,283 597 388 7,880 7,671
Other/not
speciﬁed
N/A N/A 956 0 1,936 0 N/A N/A 2,892 0
Total 39,126 32,626 14,998 14,042 141,645 36,236 74,303 38,354 270,072 121,258
Abbreviations: CALiCo, Causal Variants Across the Life Course; EAGLE, Epidemiologic Architecture for Genes Linked to Environment; N/A, not
applicable.
a For studies included in the CALiCo consortium, see Table 1.
b Total number of participants with DNA available.
c Total number of persons analyzed in year 1 and/or year 2. Similar numbers are expected for years 3 and 4.
d All subjects who speciﬁed any Hispanic or Latino heritage are tabulated in this row only.
e Data on the CALiCo Hispanic/Latino participants became available starting in year 3.
f In the Multiethnic Cohort Study, Native Hawaiians and Japanese are considered separate racial/ethnic groups.
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identify problematic assays.
Analysis methods
The Statistical Analysis Committee develops recommenda-
tions for statistical analyses and ensures that these are compa-
rable among PAGE project groups. A writing group develops
the statistical analysis plan for a deﬁned cluster of pheno-
types, which is then applied by investigators in each study
to their own data. Project groups formed around speciﬁc
phenotypes develop meta-analysis plans that are then used
for a PAGE-wide analysis. PAGE does not pool individual-
level data (with the exception of the MetaboChip Pilot Study;
see below). Meta-analyses are logistically simpler and cap-
italize on analysts’ familiarity with their local data set,
allowing them to analyze their own study’s data using har-
monized variables while allowing the participation of stud-
ies with restrictions on sharing of individual-level data. Lin
and Zeng (21) have shown that there is no efﬁciency loss in
performing meta-analysis instead of pooled analysis. PAGE
investigators attempt to address common criticisms of
Table 3. Availability of Phenotype Data Across Studies in the Population Architecture Using Genomics and Epidemiology (PAGE) Study, by
Study, 2008–present
Phenotype Domain EAGLE
Study
Multiethnic
Cohort
Study
Women’s
Health
Initiative
CALiCo Consortium
ARIC
Study
CARDIA
Study
Cardiovascular
Health Study
Strong
Heart
Study
Hispanic
Community
Health
Study/Study
of Latinos
Alcohol, tobacco, and other
substances
Alcohol use X X X X X X X X
Smoking history X X X X X X X X
Anthropometrics X X X X X X X X
Biomarkers X X X X X X X X
Cancer
Breast X X X X X X
Prostate X X X X X
Colorectal X X X X X X
Lung X X X X X X
Cardiovascular
Hypertension X X
a XX X X X X
Prevalent coronary heart disease X X
a XX X X X X
Mean systolic and diastolic blood
pressures
XX X X X X X
Diabetes and renal function X X X X X X X X
General biochemistry tests X X X X X X X X
Hematology X X X X X X X
Infectious diseases and immunity X X
a XX X X X X
Inﬂammation X X X X X X X X
Neurology X X X
Nutrition and dietary supplements X X X X X X X X
Ocular X X
a XX X
Physical activity X X X X X X X X
Psychiatric X X X X X X
Reproductive health X X X X X X X X
Respiratory X X X X X X X
Skin, bone, muscle, and joint X X
a XX X X X
Speech and hearing X X X X X X
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CALiCo, Causal Variants Across the Life Course; CARDIA, Coronary Artery Risk
Development in Young Adults; EAGLE, Epidemiologic Architecture for Genes Linked to Environment.
a Phenotypes are self-reported.
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trol, and heterogeneity of statistical analyses, by sharing
unpublished data and standardizing quality control of geno-
typing and statistical analyses.
The PAGE studies have each collected data, much of it
longitudinal, on thousands of phenotypes that PAGE has
classiﬁed into tiers. One tier contains targeted high-interest
phenotypes that are carefully harmonized and subjected to
detailed cross-study analyses that may include multiple models
and covariates. Results of these analyses will appear in pri-
mary research papers. The larger tier of phenotypes, consist-
ing of virtually all of the variables collected by each study,
regardless of a priori scientiﬁc interest, will not be harmo-
nized and will be subject only to routine analysis performed
separately by investigators in each study. These analyses
will adopt additive genetic models and incorporate minimal
adjustment for covariates. Quantitative variables will be an-
alyzed both with and without logarithmic transformation,
using the amount of skewness to determine the preferred
result.
Ancestry
PAGE comprises highly ethnically diverse US popula-
tions, including several that are historically of mixed ancestry
(Table 2). The prevalences of many traits of interest in the
PAGE collaboration, such as hyperlipidemia, type 2 diabe-
tes, and most cancers, display important population differ-
ences, as do the allele frequencies for many SNPs. Careful
attention must be paid to ancestry, and the associated con-
cern for population stratiﬁcation, to avoid false-positive as-
sociation results. The individual studies in PAGE all collect
some information about ancestry but in varying degrees of
detail. In 3 of the PAGE studies, researchers are genotyping
the Kosoy et al. (22) panels of 128 ancestry informative
markers, while in the fourth they are deriving ancestry
Table 4. Sizes of Population Samples Available in the Population Architecture Using Genomics and Epidemiology (PAGE) Study, by Phenotype
and Ancestry, 2008–present
Phenotype Domain
Ethnic/Racial Group
Total
White African-
American Hispanic American
Indian
Asian, Paciﬁc Islander,
or Native Hawaiian
Alcohol, tobacco, and other substances
Alcohol use 53,884 19,526 18,648 7,739 11,229 111,026
Smoking history 56,508 21,622 20,757 7,739 11,457 118,083
Anthropometrics 56,567 21,671 20,851 7,739 11,470 118,298
Biomarker 37,481 15,056 13,014 7,577 1,884 75,012
Cancer
Breast 24,830 8,563 7,918 69 1,032 42,412
Prostate 18,597 7,970 7,819 0 959 35,345
Colorectal 24,306 8,498 7,961 66 1,080 41,911
Lung 24,467 8,133 7,540 64 334 40,538
Cardiovascular
Hypertension 47,138 16,105 12,524 7,739 6,218 89,724
Prevalent coronary heart disease 31,894 12,055 9,811 7,518 1,583 62,861
Mean systolic and diastolic blood pressures 38,157 14,899 13,067 7,518 942 74,583
Diabetes and renal function 37,168 15,270 12,750 7,518 3,313 76,019
General biochemistry tests 52,685 17,316 14,199 7,736 2,707 94,643
Hematology 52,371 16,766 13,879 7,736 2,024 92,776
Infectious diseases and immunity 36,392 9,614 13,892 446 2,039 62,383
Inﬂammation 28,250 12,367 12,171 7,399 1,187 61,374
Neurology 4,861 1,059 268 0 0 6,188
Nutrition and dietary supplements 53,884 19,526 11,531 7,739 11,229 103,909
Ocular 44,765 11,511 4,177 446 2,687 63,586
Physical activity 35,044 12,483 18,131 7,739 11,068 84,465
Psychiatric 32,407 8,533 4,299 4,142 2,039 51,420
Reproductive health 51,401 17,477 15,029 7,739 6,434 98,080
Respiratory 48,560 15,482 12,015 4,142 2,039 82,238
Skin, bone, muscle, and joint 31,809 7,806 4,893 4,142 2,984 51,634
Speech and hearing 29,186 6,694 10,662 446 2,039 49,027
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ied ancestry. Genetic data will be used separately by each
study within strata of self-reported race/ethnicity, using a prin-
cipal component approach, to adjust for admixture between
continental ancestral groups (African, European, and Asian)
(23). The leading principal components will be included as
continuous adjustment variables in linear or logistic regres-
sion analysis relating SNPs of interest to the phenotypes.
MetaboChip Pilot Study
In 2009, PAGE investigators received supplemental funding
from NHGRI under the American Recovery and Reinvest-
ment Act to undertake a pilot study in African Americans
using the MetaboChip (http://www.sph.umich.edu/csg/
kang/MetaboChip/), a high-density custom Illumina iSelect
array of 196,725 SNPs (Illumina, Inc., San Diego, California)
that focuses on variants associated with atherosclerotic-
cardiovascular and metabolic traits (M. Boehnke, University
of Michigan, personal communication, 2010). The chip has
the added value of including thousands of 1,000 Genome SNPs
(http://www.1000genomes.org/) that will facilitate transeth-
nic ﬁne mapping around key loci, complementing PAGE’s
goal of assessing whether ﬁndings for GWAS-identiﬁed var-
iants are generalizable to populations of non-European de-
scent. The MetaboChip Pilot Study was initiated when we
realized that there was a lack of generalizability of SNPs
chosen in European and European-American GWAS to the
ethnically diversePAGE sample. For the PAGE MetaboChip
Pilot Study, approximately 6,000 African-American partic-
ipants (3,500 from CALiCo/ARIC, 2,200 from the Women’s
Health Initiative, and 580 from the Multiethnic Cohort Study)
evaluated for metabolic and cardiovascular phenotypes will
be genotyped. The ﬁne mapping of risk loci for multiple
adiposity-, lipid-, and diabetes-related traits will allow us to
evaluatewhether ﬁne mapping will aid in generalization and
replication of genetic effects across populations and may
allow us to more fully and accurately evaluate population
differences (via ﬁne mapping) for a limited number of loci.
Data-sharing
In accordance with National Institutes of Health (NIH) pol-
icy on large-scale genomic data, PAGE data will be shared
with the scientiﬁc community, primarily via dbGaP. Recog-
nizing that not all studies are suitable for widespread sharing
of the genetic data of individual participants, NHGRI estab-
lished PAGE with the expectation of distributing summary
association data, which should present few, if any, obstacles
(17, 18). These summary data include study protocols and
questionnaires, phenotype variable dictionaries, summary
phenotype and genotype data, and the results of PAGE anal-
yses. These data are submitted to the Coordinating Center,
examined for consistency and for conﬁrmation that values
are within expected bounds, reformatted according to dbGaP
speciﬁcations,and submittedtodbGaP. Althoughinitial plans
for PAGE speciﬁed dissemination of aggregate data via an
open-access Web site, subsequentchanges to NIH policy (24)
(see the NIH’s GWAS Web site (http://grants.nih.gov/grants/
gwas/)) require nearlyall PAGEdatatobeaccessible onlyvia
controlled access to approved users, such as that provided
through dbGaP. Individual-level data for the ARIC, Cardiovas-
cular Health Study, Multiethnic Cohort Study, and Women’s
Health Initiative components of PAGE will also be available
through dbGaP. PAGE investigators retain exclusive rights
to submit publications developed with the data and samples
for a period of 1 year after data are released through dbGaP.
Novel data display tools
The comprehensive range of genotype-phenotype associ-
ations that PAGE investigators will analyze does not lend
itself to graphical browsing using most existing tools or re-
sources. Therefore, a novel Web-based display browser is
being developed to facilitate exploration of the analysis re-
sults andwillbeavailabletoapprovedusers.Results inPAGE
can be classiﬁed along several axes: SNP, phenotype, study,
gender, and self-described race and ethnicity. The browser
includes a ﬂexible query interface with many display options
and ﬁlters. The current browser provides 3 types of displays:
a heat map for the simultaneous presentation of large num-
bers of results (P values or effect sizes) (Web Figure 1); box
plots and bar plots to display summary statistics for quanti-
tative and categorical variables, respectively (Web Figure 2);
and a forest plot to represent a moderate number of effect
sizes, along with their conﬁdence intervals (Web Figure 3).
These graphical views will be available for all tiers of PAGE
analyses and will help identify previously unknown associa-
tions between PAGE phenotypes and PAGE variants.
DISCUSSION
The PAGE Study is designed to advance our understand-
ing of how well-replicated risk variants affect phenotypes.
PAGE has great potential for innovative contributions that
bridge genomics and population-based research. The breadth
of phenotypic data across the PAGE network and the inclu-
sion of large samples from several ethnic/racial groups al-
low us to move beyond discovery toward characterizing
each variant, by deﬁning its epidemiologic architecture.
Deﬁning the epidemiologic architecture begins with char-
acterizing the genetic association across populations. Prior
candidate gene research supports the hypothesis that genetic
effectsofmostlycodingvariationareusuallyconsistentacross
human populations (25). To date, however, GWAS are per-
formed mainly in populations of European descent (2); rely
on linkage disequilibrium to a greater extent than most can-
didate gene studies; and often identify associations in non-
coding regions and nearly always with weak effect (1). Thus,
the issue of ‘‘transferability’’ of GWAS ﬁndings to diverse
populations remains understudied and is a major topic of
post-GWAS research (2, 3, 26, 27).
Another area of GWAS follow-up research is estimating
the true population impact mature variants have on traits (28).
The design of discovery efforts generally precludes the ac-
curate estimation of genetic effect size or magnitude of risk.
Thisinaccuracyis due tothe ‘‘winner’s curse’’ phenomenon,
whereby initial assessments of risk may be overestimated,
rendering subsequent studies of similar sizes underpow-
ered (29). PAGE counters this by using very large sample
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tions in European Americans (Table 2) and to extend these
ﬁndings to diverse populations. Ascertainment bias, poten-
tially skewing effect estimates determined in case-control
studies, is mitigated in PAGE’s population-based cohorts
because of the use of population-based sampling and adjudi-
cated phenotypes. In 3 of the 4 PAGE projects (CALiCo, the
Multiethnic Cohort Study, and the Women’s Health Initia-
tive), investigators employ rigorous deﬁnitions of incident
disease and conduct extensive longitudinal follow-up, facili-
tating studies based on repeated measures and, perhaps, prog-
nosis. The fourth project (EAGLE/NHANES) is a nationally
representative cross-sectional survey of the US population
and includes meticulous measures of risk factors and traits
related to common chronic conditions. The PAGE team in-
cludes expert epidemiologic investigators who are intimately
familiar with these data sets, including participant recruit-
ment, exposure assessment, follow-up, and study design. Their
involvement in every aspect of the PAGE analyses ensures
that the complexities of these data sets and any potential biases
will be weighed in data-analysis plans and interpretation of
results.
Investigators in the PAGE cohorts have a wealth of data,
including phenotypic subtypes and intermediate phenotypes,
covariates, biomarkers, and lifestyle variables. These data are
appropriate for detailedexplorationoftheir impact ondisease
pathways, potentially elucidating mechanisms and functions.
These data also present unprecedented opportunities to assess
the roles of well-characterized modiﬁers in complex traits,
particularly gene-environment interaction models. PAGE of-
fers a unique opportunity to explore these lines of research in
several large racially and ethnically diverse populations, an
opportunity that is unavailable in existing single-site projects.
We expect that the future of genomics will include more col-
laborative efforts of this magnitude across different large stud-
ies to allow for making discoveries, interpreting ﬁndings, and
drawing generalizable conclusions relevant to public health.
Finally, PAGE Study ﬁndings will also help inform our
knowledge of complex trait biology. PAGE can examine pleio-
tropic effects by moving beyond disease-SNP associations
and exploring the role of these SNPs in intermediate disease
phenotypes (30). In doing so, we may be able to gain insight
not only into disease pathogenesis but also into gene func-
tion. For example, it would help to know whether a variant
associated with myocardial infarction is also associated with
C-reactive protein or another inﬂammatory marker, or whether
a breast cancer susceptibility locus is also associated with
circulating estrogen concentrations. Such exploration of
disease loci may help us understand their role in disease
development.
Research beyond the scope of PAGE, such as intensive
ﬁne mapping of index SNPs, discovery of variants respon-
sible for novel GWAS peaks, and (ﬁnally) functional studies
aimed at elucidating mechanisms, will be important contri-
butions to the ﬁeld. Nonetheless, PAGE will help ﬁll in the
gaps between focused candidate gene association studies
and GWAS. The PAGE Study advances efforts to determine
the population-based impact of SNPs identiﬁed in GWAS
discovery efforts. With its enormous breadth of phenotypes
and sample sizes, PAGE promises to address unanswered
questions regarding the epidemiologic architecture of GWAS-
identiﬁed variants, gene-gene and gene-environment inter-
actions, pleiotropic variants, and intermediate phenotypes to
help elucidate their function. Not only will PAGE investi-
gators publish the study’s results, they will also disseminate
aggregate and individual-level data via dbGaP and share
aggregate results via a novel display tool. PAGE is designed
to complement and extend initial GWAS ﬁndings, most no-
tably in the areas of diversity, phenotypic breadth, and epide-
miologiccontext.Coupledwithits data andsharingofresults,
PAGE is poised to be a key contributor to population-level
annotation of the human genome.
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